Document:

STOCK INCENTIVE PLAN AS AMENDED

 EXHIBIT 10.1 
 MERCURY COMPUTER SYSTEMS, INC. 
 2005 STOCK INCENTIVE PLAN 
 (as amended and restated through August 7, 2006) 
 SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS 
 The name of the plan is the Mercury Computer Systems, Inc. 2005 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and
enable the officers, employees, Non-Employee Directors and other key persons (including consultants and prospective officers) of Mercury Computer Systems, Inc. (the “Company”) and its Subsidiaries upon whose judgment, initiative and
efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company and to induce qualified individuals who have received offers of employment to become officers of the Company to enter and
remain in the employ of the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby
stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company. 
 The following terms
shall be defined as set forth below: 
 “Act” means the Securities Act of 1933, as amended, and the rules and regulations
thereunder. 
 “Administrator” is defined in Section 2(a). 
 “Award” or “Awards,” except where referring to a particular category of grant under the Plan, shall include Incentive
Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Deferred Stock Awards and Restricted Stock Awards. 
 “Board” means the Board of Directors of the Company. 
 “Code” means the Internal Revenue Code of
1986, as amended, and any successor Code, and related rules, regulations and interpretations. 
 “Committee” means the
compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent. 
 “Covered Employee” means an employee who is a “Covered Employee” within the meaning of Section 162(m) of the Code.

 “Deferred Stock Award” means Awards granted pursuant to Section 8. 
 “Effective Date” means the date on which the Plan is approved by stockholders as set forth in Section 18. 

 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations thereunder. 
 “Fair Market Value” on any given date means if the shares of Stock are listed on any national
securities exchange, or traded on the National Association of Securities Dealers Automated Quotation System (“Nasdaq”) National Market System, the closing price, if any, on the largest such exchange, or if not traded on an exchange, the
Nasdaq National Market System on the day the Award is granted, or if the date of grant is not a business day, the business day immediately preceding the date of the grant, or if there are no sales of shares of Stock on the date of grant or on the
business day immediately preceding the date of grant, the fair market value of a share of Stock shall be determined by taking a weighted average of the means between the highest and lowest sales on the nearest date before and the nearest date after
the date of grant in accordance with Treasury Regulations Section 25.2512-2. If the shares are not then either listed on any such exchange or quoted in NASDAQ/NM, the fair market value shall be the mean between the average of the
“Bid” and the average of the “Ask” prices, if any, as reported in the National Daily Quotation Service for the date of grant, or if the date of grant is not a business day, the business day immediately preceding the date of the
grant, or, if none, shall be determined by taking a weighted average of the means between the highest and lowest sales prices on the nearest date before and the nearest date after the date of grant in accordance with Treasury Regulations
Section 25.2512-2. If the fair market value cannot be determined under the preceding two sentences, it shall be determined in good faith by the Administrator. 
 “Incentive Stock Option” means any Stock Option designated and qualified as an “incentive stock option” as defined in Section 422 of the Code. 
 “Non-Employee Director” means a member of the Board who is not also an employee of the Company or any Subsidiary. 
 “Non-Qualified Stock Option” means any Stock Option that is not an Incentive Stock Option. 
 “Option” or “Stock Option” means any option to purchase shares of Stock granted pursuant to Section 5. 

“Performance Cycle” means one or more periods of time, which may be of varying and overlapping durations, as the Administrator may
select, over which the attainment of one or more performance criteria will be measured for the purpose of determining a grantee’s right to and the payment of a Restricted Stock Award or Deferred Stock Award. 
 “Restricted Stock Award” means Awards granted pursuant to Section 7. 
 “Section 409A” means Section 409A of the Code and the regulations and other guidance promulgated thereunder. 
 “Stock” means the Common Stock, par value $0.01 per share, of the Company, subject to adjustments pursuant to Section 3.

 “Stock Appreciation Right” means any Award granted pursuant to Section 6. 
  

 2 

 “Subsidiary” means any corporation or other entity (other than the Company) in which the
Company has a controlling interest, either directly or indirectly. 
 “Ten Percent Owner” means an employee who owns or is
deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. 
 SECTION 2. ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO 
                       SELECT GRANTEES AND DETERMINE AWARDS 
 (a) Committee. The Plan shall be administered by the Committee (the “Administrator”). 
 (b) Powers of Administrator. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including
the power and authority: 
  

	 	(i)	to select the individuals to whom Awards may from time to time be granted; 

  

	 	(ii)	to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards and
Deferred Stock Awards, or any combination of the foregoing, granted to any one or more grantees; 

  

	 	(iii)	to determine the number of shares of Stock to be covered by any Award; 

  

	 	(iv)	to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may
differ among individual Awards and grantees, and to approve the form of written instruments evidencing the Awards; 

  

	 	(v)	to accelerate at any time the exercisability or vesting of all or any portion of any Award; 

  

	 	(vi)	subject to the provisions of Section 5(c), to extend at any time the period in which Stock Options and Stock Appreciation Rights may be exercised; and 

 

	 	(vii)	at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to
interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and
to otherwise supervise the administration of the Plan. 

  

 3 

 All decisions and interpretations of the Administrator shall be binding on all persons, including the
Company and Plan grantees. 
 Notwithstanding the foregoing, the Administrator’s power and authority to make grants under the Plan shall
be subject to the right of the Board, upon its request, to ratify Awards granted to the Chairman and other individuals specified by the Board, and in such event, the date of grant shall be the date of Board ratification. 
 (c) Delegation of Authority to Grant Awards. The Administrator, in its discretion, may delegate to the Chief Executive Officer of the Company or
any other person designated by the Board as an “executive officer” as defined in Rule 3b-7 under the Exchange Act all or part of the Administrator’s authority and duties with respect to the granting of Awards to individuals who are
not subject to the reporting and other provisions of Section 16 of the Exchange Act or “covered employees” within the meaning of Section 162(m) of the Code. Any such delegation by the Administrator shall include a limitation as
to the amount of Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price of any Stock Option or Stock Appreciation Right, the conversion ratio or price of other Awards
and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator’s delegate or delegates that were consistent with the terms of the
Plan. 
 (d) Detrimental Activity. Unless the award agreement specifies otherwise, the Administrator may cancel, rescind, suspend,
withhold or otherwise limit or restrict any Award (whether vested or unvested, exercised or unexercised) at any time if the recipient is not in compliance with all applicable provisions of the award agreement and the Plan, or if the recipient
engages in any “Detrimental Activity.” For purposes of this Section 2, “Detrimental Activity” shall include: (i) the rendering of services for any organization or engaging directly or indirectly in any business which is
or becomes competitive with the Company, or which organization or business, or the rendering of services to such organization or business, is or becomes otherwise prejudicial to or in conflict with the interests of the Company; (ii) the
disclosure to anyone outside the Company, or the use in other than the Company’s business, without prior written authorization from the Company, of any confidential information or material, as defined in the Company’s Employee
Confidentiality Agreement or such other agreement regarding confidential information and intellectual property that the recipient the Company may enter into (collectively, the “Confidentiality Agreement”), relating to the business of the
Company, acquired by the recipient either during or after employment with the Company; (iii) the failure or refusal to disclose promptly and to assign to the Company, pursuant to the Confidentiality Agreement or otherwise, all right, title and
interest in any invention or idea, patentable or not, made or conceived by the recipient during employment by the Company, relating in any manner to the actual or anticipated business, research or development work of the Company or the failure or
refusal to do anything reasonably necessary to enable the Company to secure a patent where appropriate in the United States and in other countries; (iv) activity that results in termination of the recipient’s employment for cause;
(v) a material violation of any rules, policies, procedures or guidelines of the Company; (vi) any attempt directly or indirectly to induce any employee of the Company to be employed or perform services elsewhere or any attempt directly or
indirectly to solicit the trade or business of any current or prospective customer, supplier or partner of the 

  

 4 

 
Company; or (vii) the recipient being convicted of, or entering a guilty plea with respect to, a crime, whether or not connected with the Company.

 (e) Indemnification. Neither the Board nor the Committee, nor any member of either or any delegate thereof, shall be liable for any
act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Committee (and any delegate thereof) shall be entitled in all cases to indemnification and
reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under any directors’ and
officers’ liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. 
 SECTION 3. STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION 
 (a) Stock Issuable. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be equal to the sum of
(i) 1,960,304 (which equals the number of shares of Stock that remain available for grants under the Mercury Computer Systems, Inc. 1997 Stock Option Plan (the “1997 Plan”) on the date this Plan was adopted by the Board of Directors),
plus (ii) the number of shares of Stock underlying any grants under the 1997 Plan that are forfeited, canceled or are terminated (other than by exercise) from and after the date this Plan was adopted by the Board of Directors, minus
(iii) any shares of Stock underlying any grants made under the 1997 Plan between the date this Plan was adopted by the Board of Directors and the Effective Date, subject to adjustment as provided in Section 3(c). For purposes of this
limitation, the shares of Stock underlying any Awards that are forfeited, canceled, expire or are terminated (other than by exercise) under this Plan shall be added back to the shares of Stock available for issuance under the Plan. Shares tendered
or held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall not be available for future issuance under the Plan. In addition, upon exercise of Stock Appreciation Rights, the gross number of
shares exercised shall be deducted from the total number of shares remaining available for issuance under the Plan. Subject to such overall limitations and Section 3(c), shares of Stock may be issued up to such maximum number pursuant to any
type or types of Award; provided, however, that Stock Options or Stock Appreciation Rights with respect to no more than 200,000 shares of Stock may be granted to any one individual grantee during any one calendar year period and provided, further,
that in no event may Incentive Stock Options granted under the Plan exceed 1,960,304 shares of Stock. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company.

 (b) Effect of Awards. The grant of any full value Award (i.e., an Award other than an Option or a Stock Appreciation Right) shall
be deemed, for purposes of determining the number of shares available for issuance under Section 3(a), as an Award of one and three-quarters (1.75) shares of Stock for each such share actually subject to the Award. The grant of an Option
or a Stock Appreciation Right shall be deemed, for purposes of determining the number of shares available for issuance under Section 3(a), as an Award of one share of Stock for each such share actually subject to the Award. 
  

 5 

 (c) Changes in Stock. Subject to Section 3(d) hereof, if, as a result of any reorganization,
recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company’s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or
kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a
result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for a different number or kind of securities of the Company or any successor entity
(or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in
the form of Incentive Stock Options, (ii) the number of Stock Options or Stock Appreciation Rights that can be granted to any one individual grantee and the maximum number of shares that may be granted under a Performance-based Award,
(iii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iv) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (v) the price for each
share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Stock Options and Stock Appreciation Rights) as to
which such Stock Options and Stock Appreciation Rights remain exercisable. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment,
but the Administrator in its discretion may make a cash payment in lieu of fractional shares. 
 The Administrator may also adjust the number
of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration material changes in accounting practices or principles, extraordinary dividends, acquisitions or dispositions of stock or
property or any other event if it is determined by the Administrator that such adjustment is appropriate to avoid distortion in the operation of the Plan, provided that no such adjustment shall be made in the case of an Incentive Stock Option,
without the consent of the grantee, if it would constitute a modification, extension or renewal of the Option within the meaning of Section 424(h) of the Code. 
 (d) Mergers and Other Transactions. In the case of and subject to the consummation of (i) the dissolution or liquidation of the Company, (ii) the sale of all or substantially all of the assets of the
Company on a consolidated basis to an unrelated person or entity, (iii) a merger, reorganization or consolidation in which the outstanding shares of Stock are converted into or exchanged for a different kind of securities of the successor
entity and the holders of the Company’s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the successor entity immediately upon completion of such transaction, or
(iv) the sale of all of the Stock of the Company to an unrelated person or entity (in each case, a “Sale Event”), the Plan and all outstanding Awards granted hereunder shall terminate, unless provision is made in connection with the
Sale Event in the sole discretion of the parties thereto for the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with
appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree (after taking into account 

  

 6 

 
any acceleration hereunder). In the event of such termination, each grantee shall be permitted, within a specified period of time prior to the consummation
of the Sale Event as determined by the Administrator, to exercise all outstanding vested and exercisable Options and Stock Appreciation Rights held by such grantee. 
 Notwithstanding anything to the contrary in this Section 3(d), in the event of a Sale Event pursuant to which holders of the Stock of the Company will receive upon consummation thereof a cash payment for each
share surrendered in the Sale Event, the Company shall have the right, but not the obligation, to make or provide for a cash payment to the grantees holding vested and exercisable Options and Stock Appreciation Rights, in exchange for the
cancellation thereof, in an amount equal to the difference between (A) the value as determined by the Administrator of the consideration payable per share of Stock pursuant to the Sale Event (the “Sale Price”) times the number of
shares of Stock subject to such outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock
Appreciation Rights. 
 (e) Substitute Awards. The Administrator may grant Awards under the Plan in substitution for stock and stock
based awards held by employees, directors or other key persons of another corporation in connection with the merger or consolidation of the employing corporation with the Company or a Subsidiary or the acquisition by the Company or a Subsidiary of
property or stock of the employing corporation. The Administrator may direct that the substitute awards be granted on such terms and conditions as the Administrator considers appropriate in the circumstances. Any substitute Awards granted under the
Plan shall not count against the share limitation set forth in Section 3(a). 
 SECTION 4. ELIGIBILITY

 Grantees under the Plan will be such full or part-time officers and other employees, Non-Employee Directors and key persons (including
consultants and qualified individuals who have received offers of employment to become officers of the Company) of the Company and its Subsidiaries as are selected from time to time by the Administrator in its sole discretion. 
 SECTION 5. STOCK OPTIONS 
 (a) Grant of Stock Options. Any Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve. 
 Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a
“subsidiary corporation” within the meaning of Section 424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option. 
 Stock Options granted pursuant to this Section 5(a) shall be subject to the following terms and conditions and shall contain such additional terms
and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. Stock Options may be granted in lieu of cash compensation at the optionee’s election, subject to such terms and conditions as the
Administrator may establish. 
  

 7 

 (b) Exercise Price. The exercise price per share for the Stock covered by a Stock Option granted
pursuant to this Section 5(a) shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. 
 (c) Option Term. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years
after the date the Stock Option is granted. 
 (d) Exercisability; Rights of a Stockholder. Stock Options shall become exercisable at
such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall
have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. 
 (e) Method of Exercise. Stock Options may be exercised in whole or in part, by giving written notice of exercise to the Company, specifying the number of shares to be purchased; provided, however, that no Stock Option may be
partially exercised with respect to fewer than 50 shares. Payment of the purchase price may be made by one or more of the following methods to the extent provided in the Option Award agreement: 
  

	 	(i)	In cash, by certified or bank check or other instrument acceptable to the Administrator; 

  

	 	(ii)	Through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the optionee on the open market or that are beneficially owned by the optionee
and are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date; or 

  

	 	(iii)	By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check
payable and acceptable to the Company for the purchase price. 

 Payment instruments will be received subject to collection. The transfer to
the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance
with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Option Award agreement or applicable provisions of laws (including the satisfaction of
any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of
Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of shares attested to. 
 (f) Annual
Limit on Incentive Stock Options. To the extent required for “incentive stock option” treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with
respect to which Incentive Stock 

  

 8 

 
Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an
optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option. 
 SECTION 6. STOCK APPRECIATION RIGHTS 
 (a) Nature of Stock Appreciation Rights. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock having a value equal to the excess of the Fair Market Value of the Stock on the
date of exercise over the exercise price of the Stock Appreciation Right, which price shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant (or more than the option exercise price per share, if the Stock
Appreciation Right was granted in tandem with a Stock Option) multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. 
 (b) Grant and Exercise of Stock Appreciation Rights. Stock Appreciation Rights may be granted by the Administrator in tandem with, or
independently of, any Stock Option granted pursuant to Section 5 of the Plan. In the case of a Stock Appreciation Right granted in tandem with a Non-Qualified Stock Option, such Stock Appreciation Right may be granted either at or after the
time of the grant of such Option. In the case of a Stock Appreciation Right granted in tandem with an Incentive Stock Option, such Stock Appreciation Right may be granted only at the time of the grant of the Option. 
 A Stock Appreciation Right or applicable portion thereof granted in tandem with a Stock Option shall terminate and no longer be exercisable upon the
termination or exercise of the related Option. 
 (c) Terms and Conditions of Stock Appreciation Rights. Stock Appreciation Rights
shall be subject to such terms and conditions as shall be determined from time to time by the Administrator, subject to the following: 
  

	 	(i)	Stock Appreciation Rights granted in tandem with Options shall be exercisable at such time or times and to the extent that the related Stock Options shall be exercisable; provided,
however, that no Stock Appreciation Right may be partially exercised with respect to fewer than 50 shares. 

  

	 	(ii)	Upon exercise of a Stock Appreciation Right granted in tandem with an Option, the applicable portion of any related Option shall be surrendered. 

 SECTION 7. RESTRICTED STOCK AWARDS 
 (a) Nature of Restricted Stock Awards. A Restricted Stock Award is an Award entitling the recipient to acquire, at such purchase price (which may be zero) as determined by the Administrator, shares of Stock
subject to such restrictions and conditions as the Administrator may determine at the time of grant (“Restricted Stock”). Conditions may be based on continuing employment (or other service relationship) and/or achievement of
pre-established performance goals and objectives. The grant of a Restricted Stock Award is contingent on the 

  

 9 

 
grantee executing the Restricted Stock Award agreement. The terms and conditions of each such agreement shall be determined by the Administrator, and such
terms and conditions may differ among individual Awards and grantees. 
 (b) Rights as a Stockholder. Upon execution of a written
instrument setting forth the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Stock, subject to such conditions contained in the
written instrument evidencing the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Stock shall be accompanied by a notation on the records of the Company or the transfer agent to the
effect that they are subject to forfeiture until such Restricted Stock are vested as provided in Section 7(d) below, and (ii) certificated Restricted Stock shall remain in the possession of the Company until such Restricted Stock is vested
as provided in Section 7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. 
 (c) Restrictions. Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically
provided herein or in the Restricted Stock Award agreement. Except as may otherwise be provided by the Administrator either in the Award agreement or, subject to Section 15 below, in writing after the Award agreement is issued, if any, if a
grantee’s employment (or other service relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Stock that has not vested at the time of termination shall automatically and without any requirement of notice
to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price from such grantee or such grantee’s legal representative simultaneously with such termination
of employment (or other service relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of unvested Restricted Stock that are
represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration. 
 (d)
Vesting of Restricted Stock. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted
Stock and the Company’s right of repurchase or forfeiture shall lapse. Notwithstanding the foregoing, except in the case of retirement, death or disability, in the event that any such Restricted Stock shall have a performance-based goal, the
restriction period with respect to such shares shall not be less than one year, and in the event any such Restricted Stock shall have a time-based restriction, the total restriction period with respect to such shares shall not be less than three
years; provided, however, that Restricted Stock with a time-based restriction may become vested incrementally over such three-year period. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives
and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Stock and shall be deemed “vested.” Except as may otherwise be provided by the Administrator either in the Award agreement or, subject to
Section 15 below, in writing after the Award agreement is issued, a grantee’s rights in any shares of Restricted Stock that have not vested shall automatically terminate upon the 

  

 10 

 
grantee’s termination of employment (or other service relationship) with the Company and its Subsidiaries and such shares shall be subject to the
provisions of Section 7(c) above. 
 SECTION 8. DEFERRED STOCK AWARDS 
 (a) Nature of Deferred Stock Awards. A Deferred Stock Award is an Award of phantom stock units to a grantee, subject to restrictions and
conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of pre-established performance goals and objectives. The grant of a Deferred
Stock Award is contingent on the grantee executing the Deferred Stock Award agreement. The terms and conditions of each such agreement shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and
grantees. Notwithstanding the foregoing, except in the case of retirement, death or disability, in the event that any such Deferred Stock Award shall have a performance-based goal, the restriction period with respect to such award shall not be less
than one year, and in the event any such Deferred Stock Award shall have a time-based restriction, the total restriction period with respect to such award shall not be less than three years; provided, however, that any Deferred Stock Award with a
time-based restriction may become vested incrementally over such three-year period. At the end of the deferral period, the Deferred Stock Award, to the extent vested, shall be paid to the grantee in the form of shares of Stock. 
 (b) Election to Receive Deferred Stock Awards in Lieu of Compensation. The Administrator may, in its sole discretion, permit a grantee to elect to
receive a portion of future cash compensation otherwise due to such grantee in the form of a Deferred Stock Award. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator
and in accordance with Section 409A and such other rules and procedures established by the Administrator. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such
limitations and other terms and conditions thereon as the Administrator deems appropriate. Any deferred compensation shall be converted to a fixed number of phantom stock units based on the Fair Market Value of Stock on the date the compensation
would otherwise have been paid but for the deferral. 
 (c) Rights as a Stockholder. During the deferral period, a grantee shall have
no rights as a stockholder; provided, however, that the grantee may be credited with dividend equivalent rights with respect to the phantom stock units underlying his Deferred Stock Award, subject to such terms and conditions as the Administrator
may determine. 
 (d) Termination. Except as may otherwise be provided by the Administrator either in the Award agreement or, subject
to Section 15 below, in writing after the Award agreement is issued, a grantee’s right in all Deferred Stock Awards that have not vested shall automatically terminate upon the grantee’s termination of employment (or cessation of
service relationship) with the Company and its Subsidiaries for any reason. 
  

 11 

 SECTION 9. PERFORMANCE-BASED AWARDS TO COVERED EMPLOYEES 
 Notwithstanding anything to the contrary contained herein, if any Restricted Stock Award or Deferred Stock Award granted to a Covered Employee is
intended to qualify as “Performance-based Compensation” under Section 162(m) of the Code and the regulations promulgated thereunder (a “Performance-based Award”), such Award shall comply with the provisions set forth below:

 (a) Performance Criteria. The performance criteria used in performance goals governing Performance-based Awards granted to Covered
Employees may include any or all of the following: (i) the Company’s return on equity, assets, capital or investment: (ii) pre-tax or after-tax profit levels of the Company or any Subsidiary, a division, an operating unit or a
business segment of the Company, or any combination of the foregoing; (iii) revenue growth; (iv) operating income as a percentage of sales; (v) total stockholder return; (vi) changes in the market price of the Stock;
(vii) sales or market share; or (viii) earnings per share. 
 (b) Grant of Performance-based Awards. With respect to each
Performance-based Award granted to a Covered Employee, the Committee shall select, within the first 90 days of a Performance Cycle (or, if shorter, within the maximum period allowed under Section 162(m) of the Code) the performance criteria for
such grant, and the achievement targets with respect to each performance criterion (including a threshold level of performance below which no amount will become payable with respect to such Award). Each Performance-based Award will specify the
amount payable, or the formula for determining the amount payable, upon achievement of the various applicable performance targets. The performance criteria established by the Committee may be (but need not be) different for each Performance Cycle
and different goals may be applicable to Performance-based Awards to different Covered Employees. 
 (c) Payment of Performance-based
Awards. Following the completion of a Performance Cycle, the Committee shall meet to review and certify in writing whether, and to what extent, the performance criteria for the Performance Cycle have been achieved and, if so, to also calculate
and certify in writing the amount of the Performance-based Awards earned for the Performance Cycle. The Committee shall then determine the actual size of each Covered Employee’s Performance-based Award, and, in doing so, may reduce or eliminate
the amount of the Performance-based Award for a Covered Employee if, in its sole judgment, such reduction or elimination is appropriate. 
 (d) Maximum Award Payable. The maximum Performance-based Award payable to any one Covered Employee under the Plan for a Performance Cycle is 300,000 Shares (subject to adjustment as provided in Section 3(c) hereof). 

SECTION 10. TRANSFERABILITY OF AWARDS 
 (a) Transferability. Except as provided in Section 10(b) below, during a grantee’s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee’s legal representative
or guardian in the event of the grantee’s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution. No Awards shall be subject,
in whole or in part, to 

  

 12 

 
attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void. 
 (b) Committee Action. Notwithstanding Section 10(a), the Administrator, in its discretion, may provide either in the Award agreement
regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Awards (other than any Incentive Stock Options) to his or her immediate family members, to trusts for the benefit of
such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award.

 (c) Family Member. For purposes of Section 10(b), “family member” shall mean a grantee’s child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the
grantee’s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of
assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests. 
 (d) Designation
of Beneficiary. Each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee’s death. Any such
designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have
predeceased the grantee, the beneficiary shall be the grantee’s estate. 
 SECTION 11. TAX WITHHOLDING

 (a) Payment by Grantee. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other
amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local
taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due
to the grantee. The Company’s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. 
 (b) Payment in Stock. Subject to approval by the Administrator, a grantee may elect to have the Company’s minimum required tax withholding
obligation satisfied, in whole or in part, by (i) authorizing the Company to withhold from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected)
that would satisfy the withholding amount due, or (ii) transferring to the 

  

 13 

 
Company shares of Stock owned by the grantee with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the
withholding amount due. 
 SECTION 12. CHANGE OF CONTROL 
 (a) Occurrence of Change of Control. Upon the consummation of a Change of Control of the Company, as defined in Section 12(b), 50% of the
unvested Awards of each grantee with a minimum of six months of service will automatically be fully vested. In the event the Change of Control of the Company is not approved by the Board of Directors, all of the outstanding Awards will automatically
become fully vested upon the consummation of the Change of Control of the Company. 
 (b) Definition. For purposes of the Plan, a
“Change of Control of the Company” shall be deemed to have occurred upon the occurrence of any of the following events: 
  

	 	(i)	any “Person,” as such term is used in Sections 13(d) and 14(d) of the Exchange Act (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other
person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Exchange
Act) of such person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50 percent or more of the combined voting power of
the Company’s then outstanding securities having the right to vote in an election of the Company’s Board of Directors (“Voting Securities”) (in such case other than as a result of an acquisition of securities directly from the
Company or an acquisition of securities involving a Corporate Transaction of the type described in the exclusion set forth in clause (iii) below); or 

  

	 	(ii)	 persons who, as of the date hereof, constitute the Company’s Board of Directors (the “Incumbent Directors”) cease for any reason, including, without
limitation, as a result of a tender offer, proxy contest, merger or similar transaction, to constitute at least a majority of the Board, provided that any person becoming a director of the Company subsequent to the date hereof shall be considered an
Incumbent Director if such person’s election was approved by or such person was nominated for election by either (A) a vote of at least a majority of the Incumbent Directors or (B) a vote of at least a majority of the Incumbent
Directors who are members of a nominating committee comprised, in the majority, of Incumbent Directors; but provided further, that any such person whose initial assumption of office is in connection with an actual or threatened election contest
relating to the election of members of the Board of Directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board, including by reason of agreement 

  

 14 

 
intended to avoid or settle any such actual or threatened contest or solicitation, shall not be considered an Incumbent Director; or 
  

	 	(iii)	the consummation of a consolidation, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company (a “Corporate
Transaction”); excluding, however, a Corporate Transaction in which the stockholders of the Company immediately prior to the Corporate Transaction, would, immediately after the Corporate Transaction, beneficially own (as such term is defined in
Rule 13d-3 under the Exchange Act), directly or indirectly, shares representing in the aggregate more than 50 percent of the voting shares of the corporation issuing cash or securities in the Corporate Transaction (or of its ultimate parent
corporation, if any). 

 Notwithstanding the foregoing, a “Change of Control of the Company” shall not be deemed to
have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities by the Company that, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of shares of
Voting Securities beneficially owned by any person to 50 percent or more of the combined voting power of all then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the
beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter
beneficially owns 50 percent or more of the combined voting power of all then outstanding Voting Securities, then a “Change of Control of the Company” shall be deemed to have occurred for purposes of the foregoing clause (i). 

SECTION 13. ADDITIONAL CONDITIONS APPLICABLE TO 
                         NONQUALIFIED DEFERRED COMPENSATION UNDER SECTION 409A. 
 In the event any Stock Option or Stock Appreciation Right under the Plan is granted with an exercise price of less than 100 percent of the Fair Market
Value on the date of grant (regardless of whether or not such exercise price is intentionally or unintentionally priced at less than Fair Market Value), or such grant is materially modified and deemed a new grant at a time when the Fair Market Value
exceeds the exercise price, or any other Award is otherwise determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code (a “409A Award”), the following additional conditions
shall apply and shall supersede any contrary provisions of this Plan or the terms of any agreement relating to such 409A Award. 
 (a)
Exercise and Distribution. Except as provided in Section 13(b) hereof, no 409A Award shall be exercisable or distributable earlier than upon one of the following: 
  

	 	(i)	Specified Time. A specified time or a fixed schedule set forth in the written instrument evidencing the 409A Award, but not later than after the expiration of ten years from
the date such Award was granted. 

  

 15 

	 	(ii)	Separation from Service. Separation from service (within the meaning of Section 409A) by the 409A Award grantee; provided, however, that if the 409A Award grantee is a
“key employee” (as defined in Section 416(i) of the Code without regard to paragraph (5) thereof) and any of the Company’s Stock is publicly traded on an established securities market or otherwise, exercise or distribution
under this Section 13(a)(ii) may not be made before the date that is six months after the date of separation from service. 

  

	 	(iii)	Death. The date of death of the 409A Award grantee. 

  

	 	(iv)	Disability. The date the 409A Award grantee becomes disabled (within the meaning of Section 13(c)(ii) hereof). 

  

	 	(v)	Unforeseeable Emergency. The occurrence of an unforeseeable emergency (within the meaning of Section 13(c)(iii) hereof), but only if the net value (after payment of the
exercise price) of the number of shares of Stock that become issuable does not exceed the amounts necessary to satisfy such emergency plus amounts necessary to pay taxes reasonably anticipated as a result of the exercise, after taking into account
the extent to which the emergency is or may be relieved through reimbursement or compensation by insurance or otherwise or by liquidation of the grantee’s other assets (to the extent such liquidation would not itself cause severe financial
hardship). 

  

	 	(vi)	Change in Control Event. The occurrence of a Change in Control Event (within the meaning of Section 13(c)(i) hereof), including the Company’s discretionary exercise
of the right to accelerate vesting of such grant upon a Change in Control Event or to terminate the Plan or any 409A Award granted hereunder within 12 months of the Change in Control Event. 

 (b) No Acceleration. A 409A Award may not be accelerated or exercised prior to the time specified in Section 13(a) hereof, except in the case
of one of the following events: 
  

	 	(i)	Domestic Relations Order. The 409A Award may permit the acceleration of the exercise or distribution time or schedule to an individual other than the grantee as may be
necessary to comply with the terms of a domestic relations order (as defined in Section 414(p)(1)(B) of the Code). 

  

	 	(ii)	Conflicts of Interest. The 409A Award may permit the acceleration of the exercise or distribution time or schedule as may be necessary to comply with the terms of a
certificate of divestiture (as defined in Section 1043(b)(2) of the Code). 

  

	 	(iii)	 Change in Control Event. The Administrator may exercise the discretionary right to accelerate the vesting of such 409A Award upon a Change in Control Event
or to terminate the Plan or any 409A Award 

  

 16 

 
granted thereunder within 12 months of the Change in Control Event and cancel the 409A Award for compensation. 
 (c) Definitions. Solely for purposes of this Section 13 and not for other purposes of the Plan, the following terms shall be defined as set
forth below: 
  

	 	(i)	“Change in Control Event” means the occurrence of a change in the ownership of the Company, a change in effective control of the Company, or a change in the ownership of a
substantial portion of the assets of the Company (as defined in IRS Notice 2005-1, Q&A-11, Q&A-12, Q&A-13 and Q&A-14 or any subsequent guidance). 

  

	 	(ii)	“Disabled” means a grantee who (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that
can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or (ii) is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can
be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under an accident and health plan covering employees of the Company or its Subsidiaries.

  

	 	(iii)	“Unforeseeable Emergency” means a severe financial hardship to the grantee resulting from an illness or accident of the grantee, the grantee’s spouse, or a dependent
(as defined in Section 152(a) of the Code) of the grantee, loss of the grantee’s property due to casualty, or similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the grantee.

 SECTION 14. TRANSFER, LEAVE OF ABSENCE, ETC. 
 For purposes of the Plan, the following events shall not be deemed a termination of employment: 
 (a) a transfer to the employment of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another; or 

(b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee’s right to
re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing. 
 SECTION 15. AMENDMENTS AND TERMINATION 
 The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but
no such action shall adversely affect rights under any 

  

 17 

 
outstanding Award without the holder’s consent. Except as provided in Section 3(c) or 3(d), in no event may the Administrator exercise its
discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect repricing through cancellation and re-grants. Any material Plan amendments (other than amendments that curtail the scope of the Plan),
including any Plan amendments that (i) increase the number of shares reserved for issuance under the Plan, (ii) expand the type of Awards available under, materially expand the eligibility to participate in, or materially extend the term
of, the Plan, or (iii) materially change the method of determining Fair Market Value, shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. In addition, to the extent determined by the
Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code or to ensure that compensation earned under Awards qualifies as performance-based compensation
under Section 162(m) of the Code, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. Nothing in this Section 15 shall limit the Administrator’s authority to take any
action permitted pursuant to Section 3(c) or 3(d). Notwithstanding the foregoing, upon approval of the Company’s shareholders, the Administrator may provide for, and the Company may implement, a one-time only exchange of certain Stock
Options for Restricted Stock Awards or Deferred Stock Awards pursuant to the terms of an exchange program described in the Company’s proxy statement relating to the special meeting of shareholders called to be held on August 7, 2006.

 SECTION 16. STATUS OF PLAN 
 With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general
creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the
Company’s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence. 
 SECTION 17. GENERAL PROVISIONS 
 (a) No Distribution; Compliance with Legal Requirements. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is
acquiring the shares without a view to distribution thereof. 
 No shares of Stock shall be issued pursuant to an Award until all applicable
securities law and other legal and stock exchange or similar requirements have been satisfied. The Administrator may require the placing of such stop-orders and restrictive legends on certificates for Stock and Awards as it deems appropriate.

 (b) Delivery of Stock Certificates. Stock certificates to grantees under this Plan shall be deemed delivered for all purposes when
the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company. Uncertificated Stock shall be 

  

 18 

 
deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of
receipt) or by United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic “book entry”
records). Stock Certificates or uncertified Stock for any Restricted Stock Award shall be delivered to the Secretary of the Company to be held in escrow until the Award becomes vested. 
 (c) Other Compensation Arrangements; No Employment Rights. Nothing contained in this Plan shall prevent the Board from adopting other or
additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to
continued employment with the Company or any Subsidiary. 
 (d) Trading Policy Restrictions. Option exercises and other Awards under
the Plan shall be subject to such Company’s applicable insider trading policy and procedures, as in effect from time to time. 
 SECTION 18. EFFECTIVE DATE OF PLAN 
 This Plan shall become effective upon approval by the holders of a majority of the
votes cast at a meeting of stockholders at which a quorum is present. Subject to such approval by the stockholders and to the requirement that no Stock may be issued hereunder prior to such approval, Stock Options and other Awards may be granted
hereunder on and after adoption of this Plan by the Board. No grants of Stock Options and other Awards may be made hereunder after the tenth (10th) anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth (10th) anniversary of the date the Plan is approved by the Board. 
 SECTION 19. GOVERNING LAW 
 This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts, applied without regard to conflict of law principles. 
 DATE APPROVED BY BOARD OF DIRECTORS:             September 14, 2005; June 1, 2006 

DATE APPROVED BY STOCKHOLDERS:
                        November 14, 2005; August 7, 2006 
  

 19Biopharmaceutical Manufacturing Services Agreement dated April 24, 2006

 Exhibit 10.1 
 BIOPHARMACEUTICAL MANUFACTURING SERVICES AGREEMENT 
 This BIOPHARMACEUTICAL MANUFACTURING SERVICES AGREEMENT, effective as
of this 24th day of April, 2006 (the “Effective Date”), by and between SEATTLE GENETICS, INC., a
Delaware corporation (“Customer”), having its principal place of business at 21823 30th Drive SE, Bothell, WA 98021 and LAUREATE PHARMA, INC., a Delaware corporation (“Laureate”), having a principal place of
business at 201 College Road East, Princeton, NJ 08540, (each a “Party”, collectively the “Parties”). 
 W I
T N E S S E T H: 
 WHEREAS, Laureate provides a full range of bioprocessing services to the biopharmaceutical industry, including
cell line development, process development, protein production, cell culture, protein purification, bioanalytical chemistry, aseptic filling and QC testing. 
 WHEREAS, Customer desires Laureate to perform services in accordance with the terms of this Agreement and the Scope (as hereinafter defined) related to the technology transfer of process information and cGMP
manufacture of monoclonal antibodies SGN-70 and SGN-33, produced by their corresponding cell lines, as well as the final dosage form of the pharmaceutical medicine containing such antibodies, and Laureate desires to perform such services.

 NOW, THEREFORE, in consideration of the above statements and other good and valuable consideration, the sufficiency and receipt of which
are hereby acknowledged, the Parties hereto agree as follows: 
 Section 1. Definitions. Terms defined elsewhere in this Agreement shall have the
meanings set forth therein for all purposes of this Agreement unless otherwise specified to the contrary. The following terms shall have the meaning set forth below in this Section 1: 
 1.1 “Affiliate(s)” for purposes of this Agreement shall mean any person, firm, trust, partnership, corporation, company or other entity
or combination thereof which directly or indirectly: (i) controls a Party; (ii) is controlled by a Party; or (iii) is under common control with a Party. As used in this definition, the terms “control” and
“controlled” shall mean ownership of fifty percent (50%) or more (including ownership by trusts with substantially the same beneficial interests) of the voting and equity rights of such person, firm, trust, partnership, corporation,
company or other entity or combination thereof or the power to direct the management of such person, firm, trust, corporation or other entity or combination thereof. 
 1.2 “Agreement” means this document as signed by the Parties including the Scope and any referenced attachments, appendices or exhibits and any amendments and additions to this document. 

1.3 “Average Yield” shall have the meaning set forth in Section 7.4. 
 1.4 “Batch” means a number of vials/bottles of Drug Product, each filled at the same time with the same Lot or a group of Lots of Drug
Substance. 
  

 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been
filed separately with the Securities and Exchange Commission. 

 1.5 “Batch Record” means a manufacturing record for a Batch generated by Laureate and
approved by Customer made concurrently with the performance of each step of the production, purification and aseptic filling process for the Product such that successive steps in such processes may be traced and which record is prepared in
accordance with 21 C.F.R. §211.188, as applicable. 
 1.6 “Cell Line” means the Chinese Hamster Ovary (CHO) cells or
SP2/0 cell line that has been designed and engineered to produce the corresponding Drug Substance as shown in Appendix 1, supplied by Customer to Laureate, particulars of which are set out in the Scope, as well as all cell banks created therefrom.

 1.7 “Change in Scope” shall have the meaning set forth in Section 2.2. 
 1.8 “Change Order” shall have the meaning set forth in Section 6.1(b) 
 1.9 “Claim” shall have the meaning set forth in Section 18.1. 
 1.10 “Customer Confidential Information” means all information, including, but not limited to, business, technical or financial data
concerning the Cell Line or Product supplied by Customer to Laureate, as well as all Customer Inventions and Customer Know-How. 
 1.11
“Customer Inventions” means any ideas, innovations or inventions (whether or not patentable) developed by Customer or Customer’s Affiliates (alone, or in conjunction with Third Parties, including Laureate) during the Term and
relating to the Drug Substance and Drug Product, including the Process. 
 1.12 “Customer Know-How” means all proprietary,
non-patented technical data, drawings, documentation, analytical and regulatory information and other information, including all improvements thereto, not included in Customer Patent Rights, as defined below, relating to the Product that is either
(a) owned by Customer (or Customer’s Affiliates), or licensed to Customer, with the right to sublicense, prior to or during the Term, (b) generated by Customer during the Term (including Customer Inventions), or (c) acquired by
Customer (other than from or on behalf of Laureate) during the Term. 
 1.13 “Customer Patent Rights” means the United
States and foreign patents and patent applications, including divisions, continuations, continuations-in-part, additions, renewals, extensions, re-examinations and reissues of all such patents and patent applications, all as are owned by Customer
(or Customer’s Affiliates), or licensed to Customer, with the right to sublicense, claiming Drug Substance and Product, or to which Laureate would need a license or sublicense in order to manufacture Drug Substance or Product. 
 1.14 “Customer Representative” shall have the meaning set forth in Section 3.2(a). 
 1.15 “Debarred Entity” shall have the meaning set forth in Section 19.1. 
 1.16 “Deficiency” shall have the meaning set forth in Section 7.1(b). 
 1.17 “Deficiency Notice” shall have the meaning set forth in Section 7.1(b). 
  

 -2- 

 1.18 “Drug Product” means the final dosage form pharmaceutical medicine containing Drug
Substance that Customer or its Affiliates will use for clinical trials. 
 1.19 “Drug Substance” means the bulk purified
monoclonal antibody protein produced and purified using the Cell Line and the Process. 
 1.20 “Effective Date” shall have
the meaning set forth in the first paragraph of this Agreement. 
 1.21 “Facility” means Laureate’s manufacturing
facility located at [***]. 
 1.22 “FDA” means the United States Food and Drug Administration, or any successor entity
thereto having substantially the same functions. 
 1.23 “Filling Components” means vials, stoppers and crimps used for an
aseptic fill of the Drug Product. 
 1.24 “Good Manufacturing Practices” or “GMP” or
“cGMP” means current good manufacturing practices, as specified in the Code of Federal Regulations and the FDA’s guidance documents as promulgated from time to time by the FDA for the manufacture and testing of pharmaceutical
products, and all successor regulations and guidance documents thereto. 
 1.25 “Indemnified Party” shall have the meaning
set forth in Section 18.4. 
 1.26 “Indemnifying Party” shall have the meaning set forth in Section 18.4.

 1.27 “Joint Inventions” shall have the meaning set forth in Section 11.3. 
 1.28 “Laureate Confidential Information” means all information, including, but not limited to, business, technical or financial data
concerning production, purification and aseptic filling process and techniques supplied by Laureate to Customer, as well as Laureate Inventions and Laureate Know-How. 
 1.29 “Laureate Group” shall have the meaning set forth in Section 18.2. 
 1.30
“Laureate Inventions” means any ideas, innovations or inventions, other than Customer Inventions, related to manufacturing (whether or not patentable), including the Laureate Process, developed by Laureate or Laureate’s
Affiliates (alone, or in conjunction with Third Parties, including Customer) during the Term. 
 1.31 “Laureate Know-How”
means all proprietary, non-patented technical data, drawings, and related documentation, including all improvements thereto, not included in Laureate Patent Rights, as defined below, relating to the process of manufacturing as developed by Laureate
prior to or during the Program that is either (a) owned by Laureate, or Laureate’s Affiliates, or licensed to Laureate, with the right to sublicense, prior to or during the Term, (b) generated by Laureate without Customer’s
participation during the Term, or (c) acquired by Laureate (other than from or on behalf of Customer) during the Term, but excluding Customer Know-How. 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -3- 

 1.32 “Laureate Patent Rights” means United States and foreign patents and patent
applications, including divisions, continuations, continuations-in-part, additions, renewals, extensions, re-examinations and reissues of all such patents and patent applications, all as are owned by Laureate, or Laureate’s Affiliates, or
licensed by Laureate, with the right to sublicense, and to which Customer would need a license in order to practice the manufacturing and/or process development operations relating to the manufacture of Drug Substance or Drug Product by Laureate for
Customer during the Program, but excluding Customer Patent Rights. 
 1.33 “Laureate Process” means any modifications,
enhancements or improvements to the Process developed by Laureate or Laureate’s Affiliates (alone, or in conjunction with Third Parties, including Customer) during the Term, which modifications, enhancements or improvements have general
applicability to any manufacturing process and not uniquely the Process. 
 1.34 “Loss” shall have the meaning set forth in
Section 18.1. 
 1.35 “Lot” means the Drug Substance produced in a single production, which may be contained in one or
more containers thereof. 
 1.36 “Materials” means Cell Lines, raw materials, reference standards and/or any other
substances to be provided by Customer to Laureate in order to undertake the Program as specified in the Scope and Appendix 1 to this Agreement. 
 1.37 “Media Fill” means a fill of bacteriological growth media into vials for validation purposes. 
 1.38 “Payment Schedule” means the schedule for Customer’s payment of Service Fees set forth in Appendix 7. 
 1.39 “Process” means the production methods and purification processes owned or controlled by Customer and disclosed to and used by Laureate for the manufacture of Drug Product, including the Drug Substance, including any
modifications, enhancements or improvements that may be made thereto, excluding the Laureate Process. 
 1.40 “Process
Consumables” means media, raw materials, filters, membranes, disposable analytical test kits, tubing, filling needles, disposable bags, disposable glass/plasticware, cleaning supplies and other changeover parts consumed during the
manufacture of Drug Substance or Drug Product. 
 1.41 “Product-Dedicated Equipment” means equipment such as chromatography
columns and resins and filters and filter housings that will be used by Laureate solely for the manufacture of Drug Substance or Drug Product pursuant to this Agreement as set forth in Appendix 10. 
 1.42 “Program” means the services to be performed by Laureate for Customer as described in the Scope. 
 1.43 “Program Manager” shall have the meaning set forth in Section 3.2(a). 
  

 -4- 

 1.44 “Quality Agreement” shall have the meaning set forth in Section 3.3(a) and is
attached hereto as Appendix 9. 
 1.45 “Regulatory Authority” means the FDA. 
 1.46 “Regulatory Filings” means the governmental filings required to commence human clinical trials and to obtain approval to market
Drug Product in a given country within the world, including, but not limited to, Drug Product registration(s) and marketing approval(s), as applicable, in each such country. 
 1.47 “Response Notice” shall have the meaning set forth in Section 7.2(a). 
 1.48 “Scope” means the detailed scope-of-work documents attached hereto as Appendix 2. 
 1.49 “Service Fees” means the fees payable by Customer set forth in Appendix 7. 
 1.50 “Shortage” shall have the meaning set forth in Section 7.4. 
 1.51 “Specifications” means the requirements for tests, analysis, test procedures and acceptable test results with which Drug Substance,
Drug Product, raw materials, in-process materials, and excipients shall conform as set forth on Appendix 3, as amended from time-to-time by the Parties. 
 1.52 “Third Party” shall mean any party other than Customer, Laureate and their respective Affiliates. 
 1.53 “Yield Target” shall have the meaning set forth in Section 7.4. 
 Section 2. Scope of
Work. 
 2.1 The Scope. A detailed Scope is attached to this Agreement as Appendix 2. Laureate will perform the Program for
Customer in accordance with the Scope. The Scope, which specifies the Program design, information desired, estimated duration of the Program, and all other matters pertinent to completion of the Program is deemed a part of this Agreement and is
incorporated herein by reference. 
 2.2 Modification of Program. If, at any time while the Program is being performed hereunder,
either Customer or Laureate desires to change the Program or Scope in a material manner, such Party shall make such request in writing, detailing the proposed changes to the Program or Scope to the other Party (a “Change in Scope”).
Within [***], Laureate shall provide Customer with a revised cost and time estimate for performing the modified Program. The Parties shall jointly review the proposed Change in Scope and revised cost and time estimate in good faith. [***]. If the
Parties agree to the Change in Scope, Appendix 2 and Appendix 7 shall be amended accordingly. 
 2.3 Program
Development. 
 (a) Laureate has consulted with Customer in developing the Program in a manner consistent with
Laureate’s current reasonable understanding of the applicable Regulatory Authority’s guidelines. However, Laureate does [***] the Program and/or the Program results will satisfy the 
  

 [***] Certain information on
this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -5- 

 
requirements of any regulatory agency at the time of submission of Regulatory Filings to such regulatory agency. Nevertheless, Laureate shall conduct the
Program diligently and in accordance with generally accepted standards of good scientific practice and, to the extent applicable, in accordance with cGMP. All work outputs (e.g., reports) will be prepared on Laureate’s standard format unless
otherwise specified in the Scope or in a written request by Customer. 
 (b) Laureate’s performance of the Program will
be based on the technical information and the Specifications in Appendix 3 provided by Customer or prepared by Laureate and approved in writing by Customer. Laureate makes [***] in accordance with the technical information provided by or
approved by Customer will result in any specific quantity or quality of Drug Substance or Drug Product. For purposes of clarity, the foregoing statement [***]. 
 2.4 Meetings. In addition to routine Program meetings, senior representatives of the Parties shall meet on an occasional basis or as necessary, the first meeting being [***] after the Effective Date, to review
progress of the Program relative to the Scope and to agree on any necessary changes to the Scope. Any disagreement between the Parties concerning the Scope (including, without limitation, the failure of the Parties to agree upon any necessary
changes to the Scope) shall be resolved in accordance with the dispute-resolution procedures set forth in Section 16 hereof. 
 Section 3.
Laureate’s Activities. 
 3.1 Services. The objective of the Program shall be for Laureate to manufacture Drug Substance
and Drug Product and to assist Customer with respect to Customer’s Regulatory Filings, as appropriate. In connection with the foregoing objective, Laureate shall provide the Facility and staff necessary to complete the Program as provided in
the Scope, as it may be modified as provided herein, including, but not limited to, the following actions: 
 (a) Sourcing
Filling Components and Process Consumables for use in manufacturing the Drug Substance and Drug Product, unless otherwise notified by Customer in writing that Customer will provide certain Filling Components or Process Consumables; 
 (b) Procuring the Product-Dedicated Equipment in accordance with the terms set forth in Section 9.2 below, including without
limitation chromatography resins. The chromatography columns will be provided to Laureate by Customer; 
 (c) Performing pilot
scale evaluation of Customer’s manufacturing processes; 
 (d) Adapting Customer’s manufacturing processes to
Laureate’s equipment and systems; 
 (e) Developing optimized process parameters to manufacture Drug Substance and Drug
Product in the Facility; 
 (f) Preparing manufacturing process documentation, including instructions and manufacturing
controls for inclusion in Regulatory Filings; 
 (g) Providing the manufacturing and quality information requested by Customer
that are necessary to support Customer’s Regulatory Filings, including, but not limited to a cross-reference 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 -6- 

 
letter to the applicable drug master files, and reasonable assistance to Customer in responding to questions from a Regulatory Authority concerning the
manufacture of Drug Substance or Drug Product; 
 (h) Conducting material contact and cleaning validation studies, engineering
and validation runs, process validation studies, and preparing process justification and validation summary reports, in a mutually agreed upon timely manner, to meet pre-approval and other appropriate inspection requirements of a Regulatory
Authority and to support approval of the manufacture of Drug Substance and Drug Product in the Facility; 
 (i) Permitting
Customer to conduct all necessary cGMP and quality assurance reviews of documentation for the Drug Substance and Drug Product, including review and receipt of copies of Batch Records; 
 (j) Permitting Customer to access Laureate’s manufacturing data relating to Drug Substance and Drug Product; 
 (k) Providing Customer Batch Records manufacturing documentation for Regulatory Filings and other uses in accordance with the Quality
Agreement; 
 (l) Manufacturing Batches or Lots of Drug Substance and Drug Product in accordance with cGMP, to the extent
applicable, and the Specifications as mutually agreed upon by the Parties in writing; and 
 (m) Using commercially reasonable
efforts to bring and maintain the Facility in compliance with EMEA and ICH guidelines. 
 3.2 Representative. 
 (a) Laureate will appoint a Laureate representative (the “Program Manager”) to be responsible for the completion of the
Program by Laureate. The Program Manager will coordinate performance of the Program with a representative designated by Customer (the “Customer Representative”), which representative shall have responsibility over all matters
relating to performance of the Program on behalf of Customer. 
 (b) Unless otherwise agreed in the Scope, or mutually agreed
to by the Parties, all communications between Laureate and the Customer regarding the conduct of the Program pursuant to the Scope shall be addressed to or routed through the Program Manager and Customer Representative. Laureate may, at its option,
substitute the Program Manager during the course of the Program. Customer may, at its option, substitute the Customer Representative during the course of the Program. 
 3.3 Quality Assurance. 
 (a) The Parties have approved a quality agreement (the
“Quality Agreement”), attached hereto as Appendix 9, which outlines the responsibilities and key contacts for quality and compliance-related issues. 
  

 -7- 

 (b) In the event any terms of the Quality Agreement conflict with or are inconsistent
with the terms of this Agreement, the terms of the Quality Agreement shall govern and control with regards to terms related to quality assurance or control, and otherwise the terms of this Agreement shall govern and control. 
 (c) Laureate shall apply its quality control procedures and in-plant quality control checks on the manufacture of Drug Substance and Drug
Product for Customer in the same manner as Laureate applies such procedures and checks to drug substance and product of a similar nature manufactured for sale by Laureate, which in all events will at least meet generally accepted standards of
quality control in the manufacture of biologics in the pharmaceutical industry. In addition, Laureate will test and release Drug Substance and Drug Product to Customer in accordance with the Specifications described in Appendix 3. 

Section 4. Customer’s Activities. 
 4.1
Customer Obligations. 
 (a) Customer will provide Laureate with sufficient Materials to perform the Program as
specified in the Scope, as well as all documentation and such other data as may be necessary to apprise Laureate of the stability of the Materials, process characteristics, proper storage, and manufacturing and safety requirements including, without
limitation, the Certificate of Analysis relating to the Cell Line and reference standards as specified in Appendix 3. 
 (b) Customer shall be responsible for the preparation and filing of Regulatory Filings, and all communications with the Regulatory Authority, with respect to Drug Substance and Drug Product. 
 Section 5. Third Parties. 
 5.1 Use by
Laureate. 
 (a) Except for the pre-approved Third Parties listed on Appendix 5, Laureate shall not utilize a Third
Party to manufacture any portion of the Drug Substance and Drug Product without first obtaining Customer’s written consent, which consent shall not be unreasonably withheld, conditioned or delayed. 
 (b) In the event that Laureate is authorized to utilize a Third Party in the manufacture of the Drug Substance and Drug Product, such
Third Party shall be approved by Laureate’s quality assurance department. 
 (c) Any contract entered into by Laureate
and a Third Party following the Effective Date shall contain provisions substantially similar to those set forth in this Agreement pertaining to the audit of Laureate, that allow Customer to audit such Third Party’s facilities, as well as
confidentiality and, to the extent applicable, intellectual property provisions substantially similar to those set forth herein. [***]. 
 (d) It shall be deemed reasonable for Customer to withhold consent to Laureate’s utilization of a Third Party to manufacture any portion of Drug Substance and Drug Product in the 
  

 [***] Certain information on
this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -8- 

 
event that such utilization would have a substantial likelihood of (i) impairing or jeopardizing any potential, pending or actual regulatory approval
for the manufacture of the Drug Substance and Drug Product, (ii) adversely affecting the regulatory status of the Drug Substance or Drug Product, (iii) materially delaying delivery schedules, increasing the pricing or adversely affecting
the quality of the Drug Substance or Drug Product or (iv) violating any applicable law, rule or regulation. 
 5.2 Use by
Customer. Laureate will not be held responsible or liable for the performance of any Third Party retained by Customer to perform services related to the Program, including, without limitation, distributors, consultants and testing entities.

 Section 6. Modification to Drug Substance or Drug Product. 
 6.1 Specifications or Process. 
 (a) Neither Party shall implement any modification, material or otherwise, to the Specifications or Process of either Drug Substance or Drug Product without the other Party’s prior written approval, provided
however that Laureate’s consent shall not be unreasonably withheld. 
 (b) To the extent that any change or modification
in Specifications or Process is agreed to by the Parties in writing (a “Change Order”) and requires a corresponding change or modification in the Service Fees (as defined below), Laureate shall submit to Customer a revised price
which reflects such cost increase or decrease resulting from the Change Order within [***] of the agreed upon Change Order. Customer and Laureate will discuss the price increase or decrease and agree upon the pricing for each Change Order. In the
event the Parties are unable to agree on a revised price as part of a Change Order, the disagreement between the parties concerning the Change Order shall be [***] and the parties shall have [***] to resolve such dispute. If at the end of such [***]
period, the parties still do not have agreement with respect to the Change Order, [***], provided, however, Laureate shall be permitted to complete the manufacture of any Lot of Drug Substance or Batch of Drug Product that it has already commenced
prior to the introduction of the Change Order and Customer shall purchase such Lot or Batch, as applicable, in accordance with the terms of this Agreement. Such Lot or Batch, as applicable, shall be manufactured in accordance with the Specifications
and Process as agreed prior to the proposed Change Order. 
 (c) All Change Orders shall be effected on a going forward basis.
Laureate shall not be expected to reprocess or retest previously manufactured Drug Substance or Drug Product unless such action is required in accordance with Section 7.2 or otherwise mutually agreed upon by the parties in a Change Order.

 (d) For clarification, this Section 6.1 shall only apply to modifications to Specifications and Process and shall not
apply to changes in Scope or Program generally, which will be conducted pursuant to the terms set forth in Section 2.2. 
 6.2
Facility. Laureate shall not make any change to the Facility which would have a material impact on the manufacture of the Drug Substance or Drug Product without prior written notice to Customer. To the extent required, Laureate shall be
responsible for obtaining all necessary approvals from the Regulatory Authority prior to implementing such change to the Facility. The cost of implementing such change to the Facility shall be the sole responsibility of Laureate unless the Facility
change was necessary solely to accommodate the manufacture of the Drug Substance or the Drug 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 
  

 -9- 

 
Product, in which case, Customer shall be responsible for the cost of implementing such change and for the cost of obtaining all necessary approvals from the
Regulatory Authority if such change is agreed upon in writing by Customer prior to such change being implemented. 
 6.3 Approval
Procedure. 
 (a) For the purposes of this Section 6, prior written approval of Customer shall mean the written
approval of Customer’s Senior Vice President, Development or Chief Executive Officer and prior written approval of Laureate shall mean the written approval of Laureate’s Chief Executive Officer. 
 (b) Except as specifically set forth herein, all changes to the Specifications or Process shall be implemented pursuant to the change
control procedures set forth in the Quality Agreement. 
 Section 7. Acceptance/Rejection of Drug Substance or Drug Product. 
 7.1 Acceptance Procedure. 
 (a) Promptly after completing the manufacture and release of each Lot of Drug Substance or Batch of Drug Product pursuant to this Agreement, Laureate shall deliver to Customer (i) a mutually agreed upon quantity of samples from each
Lot of Drug Substance or Batch of Drug Product and (ii) all accompanying quality assurance documents as required under in the Quality Agreement, including, without limitation, the Certificate of Analysis. 
 (b) Within [***] after receipt of all items required in the foregoing subsection (a), Customer shall give Laureate written notice (a
“Deficiency Notice”) of any Drug Substance or Drug Product that fails to comply with the Specifications or any of Laureate’s warranties stated in Section 17.3 (a “Deficiency”). In the absence of such
written notice, the Drug Substance or Drug Product shall be deemed to have been accepted by Customer on the [***]; provided, however, that Customer may request an extension of an [***] to confirm whether a Deficiency exists by providing written
notification to Laureate [***] prior to the expiration of the initial [***] period, in which case, the Drug Product or Drug Substance shall be deemed to have been accepted by Customer on the [***] if no written notice has been provided to Laureate.

 7.2 Determination of Deficiency. 
 (a) Upon receipt of a Deficiency Notice, Laureate shall have [***] to advise Customer in writing that it agrees or disagrees in good faith with the contents of such Deficiency Notice (the “Response
Notice”). If Laureate agrees, or it is determined pursuant to Section 7.2(b), that the rejected Lot of Drug Substance or Batch of Drug Product contained a Deficiency upon delivery in accordance with Sections 14.2 and 14.3 to Customer,
[***]. 
 (b) If Customer and Laureate fail to agree in good faith within [***] after Customer’s receipt of
Laureate’s Response Notice whether such Drug Substance has a Deficiency, Laureate shall not use any Drug Substance in dispute for the manufacture of Drug Product. The Parties shall promptly mutually select an independent laboratory to evaluate
(using the test methods described in the Specifications) if there is a Deficiency with respect to such Drug Substance or Drug Product. 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 
  

 -10- 

 
Absent manifest error, the determination of the independent laboratory shall be binding on the Parties. If the independent laboratory determines that there
is a Deficiency with respect to such Drug Substance or Drug Product, Laureate shall, at its cost and at Customer’s discretion, [***]. If the independent laboratory determines that there is no Deficiency with respect to such Drug Substance or
Drug Product, then Customer shall be deemed to have accepted delivery of such Drug Substance or Drug Product upon the independent laboratory’s issuance of its determination and Customer shall pay for the costs of the independent laboratory.

 7.3 Rejection. Subject to the provisions of Section 7.1 and 7.2, Customer has the right to reject and return, [***], any
portion of any shipment of Drug Substance or Drug Product that has a Deficiency, without invalidating any remainder of such shipment, to the extent that such Deficiency arises from Laureate’s failure to manufacture and supply the Drug Substance
and Drug Product in accordance with Specifications or its warranties set forth in Section 17.3. In such event, Laureate, [***] and at Customer’s discretion, shall promptly replace such rejected amounts with Drug Substance or Drug Product
that does not have a Deficiency [***] with respect to the portion of the Lot of Drug Substance or Batch of Drug Product so rejected. The foregoing shall be Customer’s [***] for Laureate’s delivery of Drug Substance or Drug Product
containing a Deficiency. 
 7.4 Shortages. A [***] shall be set following the successful completion of [***] described as [***] and
for [***] following successful completion of the[***] described as part of [***]. A “Shortage” shall occur if: (a) [***]. In the case of a Shortage, Laureate shall manufacture [***] a sufficient amount of Drug Substance and/or Drug
Product to compensate for such Shortage. If the Shortage is of [***], the parties will negotiate in good faith a remedy for such Shortage, which may include, but is not limited to, [***] or [***] to account for such Shortage [***]. 
 Section 8. Facility Visits and Audits. Customer’s representatives may visit the Facility at appropriate times consistent with the Program to observe the
progress of the Program or to audit the Program subject to the limitations provided in Appendix 6 to this Agreement. In addition, Laureate will have the right to audit any Third Party or Customer sites or laboratories used by Customer or any
Third Party analytical subcontractor engaged by Customer in connection with any Materials, a Cell Line, or other materials provided by or on behalf of Customer to Laureate; [***]. 
 Section 9. Compensation. 
 9.1 Fees. In consideration for Laureate’s performance of the Program and manufacture of the Drug Substance and Drug Product in accordance with this Agreement, Customer shall pay Laureate the Service Fees set forth on Appendix
7 and in accordance with the Payment Schedule set forth on Appendix 7. Customer shall pay all undisputed invoiced amounts within [***] from the date of Laureate’s invoice, provided, however, the Parties shall cooperate to resolve all
disputed invoices expeditiously and in good faith. Late payments are subject to an interest charge of [***]. 
 9.2 Product-Dedicated
Equipment. 
 (a) Customer shall pay the cost of Product-Dedicated Equipment required for Laureate to manufacture Drug
Substance and Drug Product for Customer (including the cost of installing, calibrating and validating such equipment) plus an administrative fee of [***], provided that Customer has pre-approved in writing the purchase of such Product-Dedicated
Equipment. 
  

 [***]
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -11- 

 (b) Laureate shall advise Customer of any Product-Dedicated Equipment required and the
estimated costs associated with the purchase, installation, calibration and validation of such Product-Dedicated Equipment. Laureate must receive written approval (letter, e-mail or facsimile) from Customer Representative prior to the purchase of
any Product-Dedicated Equipment. 
 (c) Product-Dedicated Equipment shall be used exclusively for manufacturing of Drug
Substance and Drug Product hereunder, unless otherwise permitted in advance by Customer in writing. [***]. This Section 9.2 shall not apply to any replacement equipment purchased by Laureate because of obsolescence (technical or otherwise).

 (d) The Product-Dedicated Equipment anticipated to be required on or around the Effective Date is listed in Appendix
10. Customer shall own all Product-Dedicated Equipment. Customer agrees and acknowledges that, unless otherwise agreed in accordance with this Section, Customer shall remove its Product-Dedicated Equipment from Laureate’s property within
[***]. Upon such termination, if Laureate wishes to retain any such Product-Dedicated Equipment (in Laureate’s sole discretion), and Customer approves of such retention in writing, Laureate [***] for such retained Product-Dedicated Equipment
[***]. In addition to Appendix 10, Laureate shall submit updated estimates of Product-Dedicated Equipment costs for the entire Program. 
 (e) Risk of loss of all Product-Dedicated Equipment shall be retained by [***]; provided, however, that [***] shall be responsible for replacing or repairing any Product-Dedicated Equipment that is destroyed or
damaged due to [***]. All Product-Dedicated Equipment shall remain at the Facility during the Term unless approved in writing by Customer. 
 (f) Laureate shall be responsible for maintaining and servicing the Product-Dedicated Equipment at [***] the Product-Dedicated Equipment. 
 Section 10. Confidential Information/Legal Proceedings. 
 10.1 Permitted Disclosure.

 (a) Laureate will not disclose, without Customer’s written permission, Customer Confidential Information unless such
disclosure: (i) is to an Affiliate of Laureate that is under a similar obligation to keep such information confidential; (ii) is to a Third Party that has been pre-approved by Customer to conduct work on Laureate’s behalf and that is
under a similar obligation to keep such information confidential; (iii) is or becomes publicly available other than as a result of a breach of this Agreement by Laureate; (iv) is disclosed by a Third Party legally able to do so;
(v) is already known to Laureate as shown by its prior written records; (vi) is independently developed by Laureate without the use of Customer Confidential Information as shown by its prior written records; or (vii) is required by
any law, rule, regulation, order, decision, decree, subpoena or other legal process to be disclosed, in which case Laureate shall notify Customer of this request promptly prior to any disclosure to permit Customer to oppose such disclosure by
appropriate legal action. In any event, Laureate shall make any disclosures of the Customer Confidential Information received by it pursuant to this Agreement only to the extent required, and only to such persons who have a need to know. 

(b) Customer will not disclose, without Laureate’s written permission, Laureate Confidential Information unless such disclosure:
(i) is to an Affiliate of Customer that is under a similar obligation to keep such information confidential; (ii) is or becomes publicly available other than 
  

 [***] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -12- 

 
as a result of a breach of this Agreement by Customer; (iii) is disclosed by a Third Party legally able to do so; (iv) is already known to Customer
as shown by its prior written records; (v) is independently developed by Customer without the use of Laureate Confidential Information as shown by its prior written records or (vi) is required by any law, rule, regulation, order decision,
decree, subpoena or other legal process to be disclosed, in which case Customer shall notify Laureate of this request promptly prior to any disclosure to permit Laureate to oppose such disclosure by appropriate legal action. In any event, Customer
shall make any disclosures of the Laureate Confidential Information received by it pursuant to this Agreement only to the extent required, and only to such persons who have a need to know. 
 10.2 Use. Neither Party shall use the other Party’s Confidential Information except as necessary to carry out its obligation under this
Agreement. 
 10.3 Transfer of Material. Laureate will not transfer any Materials without Customer’s written permission to any
Third Party unless such transfer is to a pre-approved Third Party and is consistent with the Program. 
 10.4 Testimony. If Laureate
shall be obliged to provide testimony or records regarding the Program in any legal or administrative proceeding, then Customer shall reimburse Laureate for its reasonable out-of-pocket costs plus a reasonable hourly fee for its employees or
representatives at Laureate’s standard commercial rates, unless such testimony or records is associated with Laureate’s qualification as a manufacturer of biological product generally or if such testimony or records relate to the
negligence, misconduct or breach of this Agreement by Laureate. 
 Section 11. Inventions and Patents. 
 11.1 Customer Inventions. 
 (a) Customer shall own all proprietary rights to Customer Inventions, and may obtain patent, copyright, and/or other proprietary protection relating thereto. 
 (b) At Customer’s request, Laureate will assign to Customer any Customer Invention discovered by Laureate employees either solely or
jointly with Customer employees; provided that Customer requests such assignment, in writing, within one year of notification of such Customer Invention. If Customer requests and at Customer’s expense, Laureate will execute any and all
applications, assignments or other instruments and give testimony which shall be necessary to apply for and obtain Letters of Patent of the U.S. or of any foreign country with respect to any Customer Inventions and Customer shall compensate Laureate
at its standard commercial rate for the time devoted to such activities and reimburse it for expenses incurred. 
 (c) During
the Term, Customer hereby grants to Laureate a [***] for the sole purpose of satisfying Laureate’s obligations hereunder to Customer Know-How, Customer Patent Rights, Customer Inventions, Process and other proprietary rights reasonably
necessary to conduct the development work described in the Scope, and to comply with Laureate’s obligations hereunder, including without limitation, manufacturing Drug Product and Drug Substance. 
  

 [***] Certain information on
this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -13- 

 11.2 Laureate Inventions. 
 (a) Laureate shall own all proprietary rights to Laureate Inventions, and may obtain patent, copyright, and/or other proprietary
protection relating thereto. 
 (b) Laureate hereby grants to Customer an [***] solely for making Drug Substance and Drug
Product. Customer shall have the right to [***]. 
 (c) Laureate hereby grants to Customer an [***] for any purpose.

 (d) Prior to incorporating any Laureate Invention into the manufacturing process for Drug Substance and Drug Product,
Laureate shall (i) provide Customer with all reasonably necessary information regarding the Laureate Invention (provided that such information is within Laureate’s control and such disclosure is not prohibited or restricted by
confidentiality protections, in which event, Laureate shall use reasonable efforts to obtain appropriate waivers to permit disclosure of such information) to allow Customer to conduct intellectual property due diligence, including without limitation
all relevant patents, patent applications, and any applicable license agreements (which license agreements are subject to third party confidentiality obligations and may be redacted) and (ii) obtain Customer’s [***]. In the event that
Laureate files a patent application on a Laureate Invention that has been incorporated into the manufacturing process for the Drug Substance and Drug Product, [***]. 
 11.3 Joint Inventions. Except for inventions to be owned individually by a Party as described in Sections 11.1 or 11.2 above, each Party shall own a fifty percent (50%) undivided interest in all other
inventions, discoveries and know-how made, conceived, reduced to practice and/or otherwise generated jointly by at least one employee, agent, or other person acting for each Party in the course of this Agreement (“Joint
Inventions”). The Parties shall mutually agree upon external counsel to prepare and prosecute any patent applications, U.S. and foreign, covering Joint Inventions. The Parties shall share the expenses associated with the prosecution and
maintenance of patent applications and patents covering Joint Inventions. Notwithstanding anything to the contrary in this Agreement, any ideas, innovations or inventions related specifically to the [***] hereby assigns and shall assign to Customer
all of Laureate’s right, title and interest in and to any idea, innovation or invention related specifically to the [***]. 
 11.4
Payments due to Third Parties. [***], Customer shall be responsible for any and all payments that are associated with Third Party technology used in the making, having made, using, offering for sale, selling, importing and exporting of Drug
Substance and Drug Product. In the event that Laureate has a license to any Third Party technology related to Laureate’s manufacture of the Drug Substance and Drug Product and to which Customer has approved in writing the incorporation of such
Third Party technology into the manufacturing process for the Drug Substance and Drug Product, [***]. 
 Section 12. Independent Contractor. Laureate
shall perform the Program as an independent contractor of Customer and shall have complete and exclusive control over its Facility, equipment, employees and agents. Nothing in this Agreement or other arrangements for which it is made shall
constitute Laureate, or anyone furnished or used by Laureate in the performance of the Program, as an employee, joint venture, partner, or servant of Customer. Laureate also agrees that it shall not have any rights to receive any employee benefits
such as health insurance and accident insurance, sick leave or vacation as are in effect generally for employees of Customer. Laureate will not enter into any agreements or incur obligations on behalf of Customer nor commit Customer in any other
manner without prior written consent from a duly authorized officer or representative of Customer. 
  

[***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 
  

 -14- 

 Section 13. Insurance. During the Term, Laureate shall maintain in full force and effect, for the benefit of
Customer product liability insurance (with Laureate’s coverage extending to its obligations as a manufacturer of Drug Substance and Drug Product) in an amount of not less than [***] for each accident or occurrence and [***] in the aggregate.
Customer agrees to maintain product liability and property insurance including bodily injury, death and property damage in the amount of [***] per occurrence and [***] in the aggregate at all times, covering the Cell Line, Drug Substance, Drug
Product and Material or any harms caused by the Cell Line, Drug Substance, Drug Product and Material, [***]. At the inception of this Agreement and thereafter upon request no more than annually during the Term, [***]. 
 Section 14. Shipping; Title; Sample Retention. 
 14.1
Packaging. Laureate shall package for shipment Drug Substance or Drug Product and/or samples in accordance with Customer’s written instructions and at the Customer’s expense. 
 14.2 Shipping and Delivery. All shipments will be F.C.A. the Facility and Customer shall bear all packaging, shipping and insurance charges as per
Appendix 8. Delivery of Drug Substance or Drug Products and/or samples by Laureate shall be deemed to have taken place upon delivery to the carrier at the Facility. Shipment shall be via a carrier designated by the Customer. 
 14.3 Title and Risk of Loss. [***] Laureate shall not knowingly ship any Drug Substance or Drug Product that does not conform to the
Specifications. Each shipment of Drug Substance or Drug Product shall be accompanied by the quality assurance documentation required by the Quality Agreement. 
 14.4 Retained Samples. Laureate shall retain representative samples of Drug Substance and Drug Product for record keeping, testing and regulatory purposes. 
 Section 15. Term; Termination. 
 15.1 Term. This Agreement shall commence on the Effective Date and shall continue in full force and effect until the later of: (i) [***] or (ii) all work is completed by Laureate under the Program,
unless earlier terminated in accordance with the other provisions of this Agreement. 
 15.2 Earlier Termination. 
 (a) Customer may for any reason and at any time terminate the Program prior to completion of the Program by giving [***] days written
notice to Laureate. In such event Laureate shall comply with such notice to terminate work on the Program by the expiration of such [***] notice period and use its commercially reasonable efforts to complete all activities underway and reduce cost
to Customer, and Customer shall pay Laureate (i) [***] and (ii) all of Laureate’s costs incurred up to and through the expiration of such [***] notice period; provided, that Laureate uses reasonable commercial efforts to [***] such
costs (for each Service Fee for which the final installment payment is not due and owing prior to the expiration of such [***] period, Laureate shall be compensated for the services performed with respect to such Service Fee on an [***] basis based
on Laureate’s then current [***]). 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -15- 

 (b) Customer may terminate this Agreement upon [***] prior written notice to Laureate, in
the event [***] in any consecutive [***] period or [***] in respect of [***] consecutive shipments 
 (c) Either Party may
terminate this Agreement upon [***] prior written notice to the other Party in accordance with [***] of this Agreement. 
 (d)
Upon the occurrence of the following events, either Party may terminate this Agreement by giving the other Party [***] prior written notice: (i) upon the bankruptcy or insolvency of the other Party; or (ii) upon the material breach of any
provision of this Agreement by the other Party if the breach is not remedied prior to the expiration of such [***] notice period, or if the breach is of a type that cannot be remedied within [***], then a remedy promptly commenced and diligently
pursued until complete remediation. Notwithstanding the cure period specified in the preceding sentence, if Customer fails to make any payment to Laureate within the time period specified in Section 9.1 and/or Appendix 7 attached hereto,
Laureate may, in its discretion, suspend performance of the Program until Laureate receives such outstanding payment. 
 15.3 Effects of
Termination. 
 (a) The termination of this Agreement for any reason shall not relieve either Party of its obligation to
the other Party for obligations in respect of (i) compensation for services performed (Section 9.1 and Appendix 7), (ii) confidentiality of information and legal proceedings (Section 10), (iii) inventions and patents (Section 11),
(iv) insurance (Section 13), (v) term and termination (Section 15), (vi) dispute resolution (Section 16), indemnification and limit of liability (Section 18), and (vii) notice (Section 19.5). 
 (b) Upon termination of this Agreement and Customer’s reasonable request, Laureate will use commercially reasonable efforts to assist
Customer with the transfer of the manufacturing process associated with the Drug Substance and Drug Product to Customer or its designee, at Customer’s sole cost and expense. 
 (c) Upon termination of this Agreement for any reason, Laureate and Customer shall continue to maintain information about the Drug
Substance and Drug Product and its production for such time and in such manner as required by the Regulatory Authority and shall continue to respond in a timely manner to all queries and requests for information from Regulatory Authority.

 Section 16. Dispute Resolution. 
 16.1
Senior Executives. In the event any dispute shall arise between the Customer and Laureate with respect to any of the terms and conditions of this Agreement or the Program, [***], then senior executives of the Customer and Laureate shall meet
as promptly as practicable after notice of such dispute to resolve in good faith such dispute. 
 16.2 Formal Arbitration. 

(a) If the Customer and Laureate are unable to satisfactorily resolve the dispute, then such dispute shall be finally settled by
arbitration in accordance with this Section 16. The arbitration will be held in the [***], and except as noted below, shall be conducted in accordance with 
  

 [***] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -16- 

 
the rules of the American Arbitration Association (or such successor organization) by [***] appointed, one by each Party. If the arbitrators appointed cannot
agree on the resolution of the dispute within [***] after the dispute is submitted to them, they shall thereupon appoint a [***], and if they fail to agree upon a [***] within [***] after a deadlock is declared by either arbitrator, a [***] will be
appointed by the American Arbitration Association (or such successor organization) upon the request of either arbitrator. The arbitrators shall have no authority to vary from or ignore the terms of this Agreement and shall be bound by controlling
law. Finally, the Parties may seek judicial intervention for emergency relief, such as restraining orders and injunctions where appropriate. 
 (b) Any decision by the initial [***] or the [***] and either one of the initial [***] shall be binding upon the Parties and may be entered as final judgment in any court having jurisdiction. The cost of any
arbitration proceeding shall be borne by the Parties as the arbitrators shall determine if the Parties have not otherwise agreed. The arbitrators shall render their final decision in writing to the Parties. 
 Section 17. Representations and Warranties. 
 17.1
Of Both Parties. Each Party represents and warrants that as of the Effective Date such Party: 
 (a) has full power and
authority to enter into, deliver and perform its obligations under this Agreement, and it has taken all action required to authorize the execution and delivery of this Agreement and to consummate the transactions contemplated hereby, and the person
signing this Agreement on behalf of such Party has been duly authorized to act on behalf of and to bind such Party; 
 (b) is
aware of no legal, contractual or other restriction, limitation or condition that might affect adversely its ability to perform hereunder; and 
 (c) is in good standing under the laws of each state or other jurisdiction in which it is incorporated or engages in business activities. 
 17.2 Customer Representations, Warranties and Covenants. Customer represents and warrants that: 
 (a) it has all rights, title and interest in the Customer Know-How, Customer Patent Rights, Materials (including, without limitation, the Cell Lines) and Process necessary to grant the licenses it is granting under
this Agreement; 
 (b) it is and shall at all times throughout the term of this Agreement remain entitled to supply Laureate
with Materials (including, without limitation, the Cell Lines); 
 (c) there are no actions, suits or claims that have been
initiated, or to Customer’s knowledge, threatened against Customer with respect to the use of the Customer Know-How, Customer Patent Rights, Materials (including, without limitation, the Cell Lines) and Process; 
 (d) [***]; that the Materials shall be shipped to Laureate in compliance with all applicable federal, state and local laws and
regulations; 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -17- 

 (e) any technical or regulatory information or documentation supplied by Customer or on
its behalf to Laureate (including, without limitation, the Process, analytical methods, Specifications, development reports, technology transfer documents, plans, engineering documents and other documents) and required for performance of the Program
[***]; and 
 (f) if Customer becomes aware that any of its statements set forth in this subsection (d) or (e) above
are not accurate, Customer shall promptly notify Laureate of such inaccuracies. 
 17.3 Laureate Representations, Warranties and
Covenants. Laureate represents and warrants that: 
 (a) all Drug Substance and Drug Product delivered to Customer
pursuant to this Agreement shall have been manufactured in accordance with the Batch Records, the Specifications, all applicable laws and regulations in all material respects and, to the extent applicable, cGMP; 
 (b) during the Term, the Facility, equipment and practices that shall be used to perform the Program shall conform to the requirements of
all applicable laws, rules and regulations 
 (c) Drug Substance and Drug Product will not be adulterated or misbranded,
within the meaning of the U.S. Food, Drug & Cosmetics Act, or any comparable laws, rules or regulations as a result of any act or omission of Laureate; and 
 (d) [***]. 
 (e) if Laureate becomes aware that any of its statements set forth in this subsection (b) or (d) above are not accurate, Laureate shall promptly notify Customer of such inaccuracies. 
 17.4 Disclaimer. 
 (a)
EXCEPT AS EXPRESSLY SET FORTH HEREIN, CUSTOMER MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO DRUG SUBSTANCE, CUSTOMER PATENT RIGHTS, CUSTOMER KNOW-HOW, CUSTOMER CONFIDENTIAL INFORMATION, CELL LINES OR MATERIALS PROVIDED HEREUNDER.
ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT, ARE HEREBY DISCLAIMED BY CUSTOMER. 
 (b) EXCEPT AS EXPRESSLY SET FORTH HEREIN, LAUREATE MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE DRUG SUBSTANCE, DRUG
PRODUCT, LAUREATE PATENT RIGHTS, LAUREATE KNOW-HOW, LAUREATE CONFIDENTIAL INFORMATION OR MATERIALS PROVIDED HEREUNDER. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NON-INFRINGEMENT, ARE HEREBY DISCLAIMED BY LAUREATE. 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 
  

 -18- 

 17.5 Limitation on Liability. 
 (a) NOTWITHSTANDING ANY PROVISION TO THE CONTRARY IN THIS AGREEMENT, IN NO EVENT SHALL CUSTOMER OR CUSTOMER’S AFFILIATES BE LIABLE
FOR INDIRECT, INCIDENTAL, LIQUIDATED OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST REVENUES OR PROFITS. If at any time any representation or warranty to Customer’s knowledge is no longer accurate, Customer will promptly notify
Laureate of such fact. 
 (b) NOTWITHSTANDING ANY PROVISION TO THE CONTRARY IN THIS AGREEMENT, IN NO EVENT SHALL LAUREATE OR
LAUREATE’S AFFILIATES BE LIABLE FOR INDIRECT, INCIDENTAL, LIQUIDATED OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST REVENUES OR PROFITS. If at any time any representation or warranty to Laureate’s knowledge is no longer
accurate, Laureate will promptly notify Customer of such fact. 
 (c) For the avoidance of doubt, Section 17.5(a) and
Section 17.5(b) shall not affect the indemnification obligations of either Laureate or Customer pursuant to Section 18.1 or Section 18.2, respectively, to the extent that the Claim (as defined below) is a result of direct damages to
such Third Party making such Claim. 
 Section 18. Indemnification and Limit of Liability. 
 18.1 Laureate. Laureate shall defend, indemnify and hold harmless Customer and its Affiliates and their respective officers, directors and
employees from any liability, judgment loss, cost, damage or other expense (a “Loss”) from any Third Party-lawsuit, action, claim, demand, assessment or proceeding (a “Claim”) arising from or based on: 

(a) Laureate’s gross negligence or willful misconduct in the development, testing, use, storage, handling, packaging, labeling,
manufacture, or delivery of Drug Substance or Drug Product; 
 (b) any manufacturing procedures, methods or techniques (or
component thereof) [***]; or 
 (c) Laureate’s or its Affiliates’ breach of this Agreement; 
 provided, that, if such Loss or Claim arises in whole or in part from the events described in Section 18.2 below, then the amount of the Loss that Laureate shall
indemnify Customer for pursuant to this Section 18 shall be reduced by an amount in proportion to the percentage of Customer’s responsibilities for such Loss. 
 18.2 Customer. Customer shall defend, indemnify and hold harmless Laureate and its Affiliates and their respective officers, directors, employees and agents (the “Laureate Group”) from any
Claim or Loss arising from or based on: 
 (a) Customer’s gross negligence or willful misconduct in connection with the
performance of its obligations under this Agreement or the Program, including without limitation, the development, testing, use, manufacture, promotion, marketing, sale, distribution, packaging, labeling, handling, storage and/or disposal of Drug
Substance or Drug Product; 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -19- 

 (b) the infringement of any patents or other intellectual property rights vested in any
Third Party by the Process, Cell Line or Drug Substance or Drug Product; or 
 (c) Customer’s and its Affiliate’s
breach of this Agreement; or 
 (d) the harmful or otherwise unsafe effect, including personal injury or property damage, to
any Third Party (excluding the Laureate Group) directly or indirectly caused by the Cell Line, Materials, Product-Dedicated Equipment, Process Consumables, Drug Substance or Drug Product; 
 provided, that, if such Loss or Claim arises in whole or in part from the events described in Section 18.1 above, then the amount of such Loss that Customer shall
indemnify the Laureate Group for pursuant to this Section 18 shall be reduced by an amount in proportion to the percentage of Laureate’s responsibilities for such Loss. 
 18.3 Assumption of Liability. 
 (a) [***] for any and all direct damages to Laureate in the event that the handling of Cell Line, Materials, Process Consumables, Drug Product or Drug Substance on its premises, or the use of the Product-Dedicated Equipment, in accordance
with Laureate SOP, the Scope and the terms of this Agreement [***], as initially received by Laureate, and to the extent that said [***]. For purposes of the preceding sentence, [***] shall be deemed to include [***] awarded by an arbitrator, a
court of law or other governing tribunal or agency which determines [***] to be responsible and/or liable by virtue of its handling of Materials, Process Consumables, Drug Product or Drug Substance on its premises, or the use of the
Product-Dedicated Equipment, in accordance with Laureate SOP, the Scope and the terms of this Agreement; provided, [***]. [***]. To the extent that any contamination of equipment, facilities, personnel or Third Parties results from Laureate’s
negligence, willful misconduct or failure to follow its SOP, the terms of this Agreement or care considered standard in the industry, [***]. 
 (b) Laureate agrees to use commercially reasonable efforts to mitigate any direct damages in the event of a contamination incident caused by Materials, Process Consumables, Drug Products, Drug Substance or associated
materials. 
 (c) [***] in the event that the Cell Line, Materials, Process Consumables, Drug Product or Drug Substance or
associated materials are [***]. For purposes of the preceding sentence, [***] shall be deemed to include [***] awarded by an arbitrator, a court of law or other governing tribunal or agency which determines [***] to be responsible and/or liable by
virtue of its use of the Materials, Process Consumables, Drug Product or Drug Substance or the use of the Product-Dedicated Equipment, in accordance with Customer SOP, the Scope and the terms of this Agreement; provided, [***]. 
 (d) To the extent that any contamination results from Customer’s negligence, willful misconduct or failure to follow its SOP, the
terms of this Agreement or care considered standard in the industry, [***]. 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 
  

 -20- 

 (e) Customer agrees to use commercially reasonable efforts to mitigate any direct damages
in the event of a contamination incident caused to the Materials, Process Consumables, Drug Products, Drug Substance or associated materials. 
 18.4 Procedure for Indemnification. Upon receipt of notice of any Claim that may give rise to a right of indemnity from the other Party hereto, the Party seeking indemnification (the “Indemnified Party”) shall give
written notice thereof to the other Party, (the “Indemnifying Party”) of the Claim for indemnity. Such Claim for indemnity shall indicate the nature of the Claim and the basis therefore. Promptly after a claim is made for which the
Indemnified Party seeks indemnity, the Indemnified Party shall permit the Indemnifying Party, at its option and expense, to assume the complete defense of such Claim, provided, that, (i) the Indemnified Party will have the right to participate
in the defense of any such Claim at its own cost and expense; (ii) the Indemnified Party may assume the complete defense of such claim at the Indemnifying Party’s cost and expense if the Indemnified Party shall have reasonably concluded
upon the advice of outside counsel, that there is a conflict of interest between the Indemnified Party and the Indemnifying Party; (iii) the Indemnifying Party will conduct the defense of any such Claim with due regard for the business
interests and potential related liabilities of the Indemnified Party; and (iv) the Indemnifying Party will, prior to making any settlement, consult with the Indemnified Party as to the terms of such settlement. The Indemnifying Party will not,
in defense of any such Claim, except with the consent of the Indemnified Party, consent to the entry of any judgment or enter into any settlement which does not include, as an unconditional term thereof, the giving by the claimant or plaintiff to
the Indemnified Party of a release from all liability in respect thereof. After notice to the Indemnified Party of the Indemnifying Party’s election to assume the defense of such Claim, the Indemnifying Party shall only be liable to the
Indemnified Party for such reasonable legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof at the request of the Indemnifying Party. As to those Claims with respect to which the Indemnifying
Party does not elect to assume control of the defense, the Indemnifying Party shall be liable for all reasonable legal or other expenses incurred by the Indemnified Party in connection with the defense thereof and the Indemnified Party will afford
the Indemnifying Party an opportunity to participate in such defense at the Indemnifying Party’s own cost and expense, and will not settle or otherwise dispose of any of the same without the consent of the Indemnifying Party. 
 18.5 Limitation on Liability. In addition, Laureate shall not be liable for any damages arising from claims of Third Parties for injury, death or
property damage suffered as a result of the use of the Drug Substance or Drug Product, [***]. In no event shall Laureate’s maximum liability under this Agreement for all claims (whether or not brought by Third Parties), whether in connection
with a warranty claim, an indemnity claim, a combination thereof, or otherwise and whether arising under contract, warranty, tort (including negligence), strict liability, product liability, a combination thereof, or any other theory of liability or
indemnification shall not exceed the greater of (i) [***] or (ii) [***] of the total fees paid to Laureate during the [***] immediately prior to the claim at issue or if the claim is commenced following completion of services by Laureate,
the last [***] period in which work was performed by Laureate. The foregoing limitation shall not apply if the claims or damages are the direct result of [***]. 
 Section 19. Miscellaneous. 
 19.1 Debarment. Each of the Parties warrants and represents to the other Party that each
such Party has never been, is not currently, and, during the Term, will not become, a Debarred Entity. 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

 -21- 

 
Each of the Parties further warrants and represents that no Debarred Entity has performed or rendered, or will perform or render, any services or assistance
on its behalf relating to activities taken pursuant to this Agreement. If any of the foregoing warranties or representations becomes untrue as to a specific Party (by way of example only, if Laureate or any individual or entity performing services
on its behalf hereunder becomes excluded, debarred or suspended after the Effective Date of this Agreement), such Party shall notify the other Party and this shall constitute grounds for immediate termination by the Party which has not violated the
representations and warranties of this Section 19. This provision shall survive termination or expiration of this Agreement. “Debarred Entity” for purposed of this Section 19 means a corporation, partnership or association that
has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from submitting or assisting in the submission of any abbreviated drug application, or an employee, partner, shareholder, member, subsidiary or affiliate of a
Debarred Entity. 
 19.2 Force Majeure. Either Party shall be excused from performing its respective obligations under this Agreement
if its performance is delayed or prevented by any event beyond such Party’s reasonable control, including, but not limited to, acts of God, fire, explosion, weather, disease, war, terrorism, insurrection, civil strife, riots, government action,
or power failure, provided that such performance shall be excused only to the extent of and during such disability. Any time specified for completion of performance in the Scope falling due during or subsequent to the occurrence of any of such
events shall be automatically extended for a period of time reasonably necessary to recover from such disability. Laureate will promptly notify Customer if, by reason of any of the events referred to herein, Laureate is unable to meet any such time
for performance specified in the Scope. If any part of the Program is invalid as a result of such disability, Laureate will, upon written request from Customer, repeat that part of the Program affected by the disability. 
 19.3 Publicity. Except as required by law or regulation, neither Party shall be permitted to disclose any of the provisions of this Agreement or
make any public announcement or public statement concerning this Agreement or its subject matter, without the prior written consent of the other Party. Notwithstanding the foregoing, either Party, without the consent of the other Party, may disclose
the general nature of this Agreement to third parties in connection with financings, corporate transactions or merger and acquisition discussions, provided that prior to such disclosure, such third parties executed confidentiality and non-disclosure
agreements with terms substantially similar to those provided for in Section 10. Each party shall be permitted to use the name and logo of the other Party in the promotion of its business. Usage shall be permitted for (i) promotional
purposes, (ii) sales and marketing materials, (iii) web sites, and (iv) other customary business uses agreed to by the Parties. Without the consent of the other Party, such usage shall be limited to general factual statements
concerning the relationship between Laureate and Customer, including, without limitation, that Laureate and Customer have entered into an agreement for the provision of production, purification and aseptic filling services to Customer but shall not
include any financial terms. 
 19.4 Assignment. This Agreement may not be assigned or otherwise transferred by either Party without
the prior written consent of the other Party; provided, however, either Party may, without such consent, assign this Agreement (i) in connection with the transfer or sale of all or substantially all of the assets of such Party or, in the case
of Customer, the Cell Line or Drug Substance or Drug Product; (ii) in the event of the merger or consolidation of a Party hereto with another company; or (iii) to any Affiliate of the assigning Party. Any purported assignment in violation
of the preceding sentence shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement, 

  

 22 

 
provided however that if Customer assigns this Agreement to an Affiliate, the Customer shall continue to remain obligated under this Agreement. 

19.5 Notice. All notices to be given as required in the Agreement shall be in writing and may be delivered personally, or mailed either by a
reputable overnight carrier with required receipt signature or certified mail, postage prepaid to the Parties at the addresses set forth above or at such other address as either Party may provide by written notice to the other Party in accordance
with the provisions of this Section 19.5. Such notice shall be effective: (i) on the date sent, if delivered personally or by facsimile (receipt of which is confirmed); (ii) the date after delivery if sent by overnight carrier; or
(iii) on the date received if sent by certified mail. 
 If to Customer: 
 Seattle Genetics, Inc. 
 21823
30th Drive SE 
 Bothell, WA 98021 
 Attn: General Counsel 
 Telefax: 425-527-4109 
 If to Laureate: 
 Laureate Pharma, Inc. 
 201 College Road
East 
 Princeton, NJ 08540 
 Attn: Chief Executive Officer 
 Telefax: (609) 520-3963 
 With a copy to: 
 Safeguard Scientifics,
Inc. 
 800 The Safeguard Building 
 435 Devon Park Drive 
 Wayne, PA 19087 
 Attn: Legal Department 
 Fax: (610) 975 - 0261 
 19.6 Choice of Law. This Agreement, and all matters arising directly or indirectly hereunder, shall be governed by, and construed in accordance
with the laws of the State of New Jersey. 
 19.7 Headings. The heading of each paragraph of this Agreement is for descriptive
purposes only and shall not be deemed to modify or qualify any of the provisions, rights, or obligations set forth in this Agreement. 
 19.8
Waiver/Severability. No waiver of any provision of this Agreement, whether by conduct or otherwise, in any one or more instances shall be deemed to be or be construed as a further or continuing waiver of any such provision, or of any other
provision or condition of this Agreement. The invalidity of any portion of this Agreement shall not affect the validity, force or effect of the remaining 

  

 23 

 
portions of this Agreement. If it is ever held that any provision hereunder is too broad to permit enforcement of such provision to its fullest extent, such
provision shall be enforced to the maximum extent permitted by law. 
 19.9 Entire Agreement; Modification/Counterparts. This document
(and the Scope and Appendices attached hereto) sets forth the entire Agreement between the Parties hereto with respect to the performance of the Program by Laureate for Customer and as such, supersedes all prior and contemporaneous negotiations,
agreements, representations, understandings, and commitments with respect thereto and shall take precedence over all terms, conditions and provisions on any purchase order form or form of order acknowledgment or other document purporting to address
the same subject matter. This Agreement shall not be waived, released, discharged, changed or modified in any manner except by an instrument signed by the duly authorized officers of each of the Parties hereto, which instrument shall make specific
reference to this Agreement and shall express the plan or intention to modify same. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same
instrument. In the event of any conflict between this Agreement and the Scope, as it may be modified as provided herein, the terms of this Agreement shall control. For purposes of execution, facsimile signatures shall be deemed originals.

  

 24 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives
on the Effective Date. 
  

			
	 LAUREATE PHARMA, INC.

		
	 By:
	 	 /s/ Robert J. Broeze, Ph.D.

	 Name:
	 	 Robert J. Broeze, Ph.D.

	 Title:
	 	 President & Chief Executive Officer

	
	 SEATTLE GENETICS, INC.

		
	 By:
	 	 /s/ Clay B. Siegall, Ph.D.

	 Name:
	 	 Clay B. Siegall, Ph.D.

	 Title:
	 	 President & Chief Executive Officer

  

 25 

 APPENDIX 1 
 Cell Lines, Materials and Drug Products 
 [***] 
  

 [***] Certain information on
this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 2 
 Scope of Work 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 3 
 Drug Product Specifications 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 4 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 5 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 6 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 7 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 7a 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 8 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 9 
 Quality Agreement 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX 10 
 [***] 
  

 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]